Government Collaborations BioAegis has engaged with BARDA DRIVe to develop plasma gelsolin for sepsis and ARDS, illustrating a track record of government funded translational programs. This presents opportunities for additional BARDA contracts, NIH collaborations, and milestone driven partnerships to accelerate development.

Academic Partnerships The UT System licensing partnership shows receptivity from major academic medical centers for gelsolin based therapies. There is potential to expand collaborations with other leading universities and medical centers for joint development, multi center trials, and licensing deals across indications like trauma, burns, renal disease and infections.

Pharma Licensing As a clinical stage focused on inflammation and infection with a novel gelsolin platform, BioAegis may attract licensing or co development deals from larger biopharma seeking novel modalities to complement their portfolios, particularly in sepsis, ARDS and related conditions. Target mid to large pharma with inflammation and critical care franchises.

Biomarker Strategy The emphasis on plasma gelsolin as both therapeutic replacement and a biomarker directed approach opens doors for companion diagnostics collaborations and patient stratification in inflammatory diseases. Propose partnerships with diagnostic companies or CROs to design biomarker guided trials and accelerate regulatory paths.

Investor Outreach Participation in investor conferences and ongoing fundraising activity signals readiness to engage strategic partners. Leverage networks to introduce BioAegis to potential pharma, CROs, academic partners, and government programs and refine the value proposition for collaboration.